NTLA vs. NEOG, MYGN, CLDX, LNTH, HSKA, QDEL, RETA, NARI, ISEE, and CYTK
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Neogen (NEOG), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Lantheus (LNTH), Heska (HSKA), QuidelOrtho (QDEL), Reata Pharmaceuticals (RETA), Inari Medical (NARI), IVERIC bio (ISEE), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Intellia Therapeutics vs.
Intellia Therapeutics (NASDAQ:NTLA) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends.
In the previous week, Intellia Therapeutics had 4 more articles in the media than Neogen. MarketBeat recorded 11 mentions for Intellia Therapeutics and 7 mentions for Neogen. Intellia Therapeutics' average media sentiment score of 0.63 beat Neogen's score of 0.30 indicating that Intellia Therapeutics is being referred to more favorably in the media.
Neogen has a net margin of -2.57% compared to Intellia Therapeutics' net margin of -909.78%. Neogen's return on equity of 5.56% beat Intellia Therapeutics' return on equity.
Intellia Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Intellia Therapeutics presently has a consensus price target of $87.18, suggesting a potential upside of 140.49%. Neogen has a consensus price target of $20.00, suggesting a potential upside of 14.88%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Neogen.
Intellia Therapeutics received 74 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 70.09% of users gave Intellia Therapeutics an outperform vote while only 58.54% of users gave Neogen an outperform vote.
85.6% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Neogen shares are held by institutional investors. 2.6% of Intellia Therapeutics shares are held by company insiders. Comparatively, 0.7% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Neogen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Summary
Intellia Therapeutics beats Neogen on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Intellia Therapeutics Competitors List